Peter Bertoli
YOU?
Author Swipe
View article: Rate of Participation in a Second Randomized Clinical Trial and Factors Associated with the Likelihood of Participation among IBD Patients who already Experienced a Randomized Clinical Trial.
Rate of Participation in a Second Randomized Clinical Trial and Factors Associated with the Likelihood of Participation among IBD Patients who already Experienced a Randomized Clinical Trial. Open
Understanding factors affecting re-participation in IBD trials is crucial to improving patient involvement in research.
View article: TL1A as a Target in Inflammatory Bowel Disease: Exploring Mechanisms and Therapeutic Potential
TL1A as a Target in Inflammatory Bowel Disease: Exploring Mechanisms and Therapeutic Potential Open
Inflammatory bowel diseases (IBD) are chronic disorders characterized by persistent inflammation of the gastrointestinal tract. Despite advances in treatment, a significant proportion of patients remain refractory to current therapies and …
View article: Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease
Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease Open
Background and Aims Criteria for “difficult-to-treat” inflammatory bowel disease (DTT-IBD) have recently been proposed to standardize terminology. We aimed to evaluate the prevalence, characteristics, management, and outcomes of DTT-IBD. M…